ArticleDiscover oncology2025
Systematic analysis of the aberrances and functional implications of epigenetic genes in hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk BetweenCancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Epigenetic alteration leads to the aberrant transcriptional programmes that faciliate cancer onset and progression. In-depth understanding of the epigenetic alteration of cancers is critical for crucial in developing meaningful cancer treatment that may provide a meaningful improvement in overall survival. Based on the data in The Cancer Genome Atlas (TCGA), we performed a comprehensive and systematic genomic study of epigenetic genes. We defined the epigenetic score to reveal the functional roles of epigenetic genes. We found that epigenetic score was higher in tumors than in normal tissues in most cancers and was associated with poorer prognosis, especially in hepatocellular carcinoma (HCC).Our study also found that epigenetic score is significantly related to immune evasion in HCC. To guide efficient pharmalogical intervention of unfolded protein response to help patients, we performed virtual screening and found some compounds targeting UHRF1 could become a good pharmaceutical therapeutic candidate in unique or adjuvant therapeutic approaches toward HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.